Zai Lab's Global Pivot: Profitability Deferred as the DLL3 ADC Goes Worldwide
The China-focused biotech is funding a global build-out behind Zoci — and quietly kicking its profit milestone down the road
ZLAB · Earnings Call · 2026-08-06
Zai Lab walked into its Q2 2026 call with a deliberate change of framing. After years of defending regional revenue guidance and reaffirming a year-end profitability target, management now wants to be talked about as a global drug developer backed by a financially self-sustaining China business.
The shift is visible in the company's own keyword trajectory, where global biopharmaceutical company positioning has entered the top tier for the first time, anchored by the control of brain metastases pitch for Zoci (ZL-1310), the DLL3-targeted ADC. Rafael Amado walked through a fast-moving program: the global Phase III in second-line-plus small cell lung cancer should complete enrollment in 1H 2027, with a U.S. accelerated approval submission later that year and approval anticipated in 2028. The data set is broadening — at ESMO in October the company will show ~60 patients of first-line combination data, and in extrapulmonary neuroendocrine carcinoma Zoci has already delivered a confirmed ORR of 38.2% versus the roughly 18% typical of current regimens. The ambition is now explicitly global: three registrational programs underway by year-end, plus combo studies with Amgen and Boehringer Ingelheim's T-cell engagers. **Profitability: the quieter deferral** The real change on this call, though, is what management stopped promising. As recently as August 2025, Josh Smiley told analysts, “we also have reconfirmed that we see us achieving profitability on a non-GAAP basis in Q4” — Joshua L. Smiley, President and Chief Operating Officer · 2025-08-07. Even in February 2026, CFO Yajing Chen framed breakeven as a near-term command, saying “our corporate profitability, I mean the cash flow breakeven is definitely continue to be a very clear objective” — Yajing Chen, Chief Financial Officer · 2026-02-26. Yesterday's language was different. Asked directly whether investors could revisit the profitability goal, Yajing answered through a capital-allocation lens:Zai Lab has reached an important inflection point in its evolution from a regional business into a global biopharmaceutical company.
That is a marked tonal shift from "clear objective" to "naturally lead to profitability over time" — an explicit choice to fund the global pipeline at the expense of a dated profit target, cushioned by $717.5M of cash (effective net cash of $447M a quarter earlier, off a $806M peak). The financials support the math: R&D intensity is high — R&D ran at about 66% of total revenue in Q1 2026 — even as the China business is nominally profitable on a product basis. The stock's reaction tells you the market is fine with the trade-off: ZLAB is up ~26% over 90 days, with a +43% surge in the last two weeks that has inflected the name off its deep drawdown (still ~86% below the January 2021 peak). **Commercial: stabilization before reacceleration** The regional engine is being tuned, not scrapped. Yizhe Wang's framing was blunt: “we must go back to the basics... It's all about underlying demand” — Yizhe Wang, Commercial Executive · 2026-08-06. Net product revenue grew 11% sequentially to $105.8M, and the company reiterated a return to meaningful growth in 2027. KarXT is the near-term x-factor — the first new schizophrenia mechanism in decades, with NRDL inclusion targeted for 2027 — while VYVGART volumes grew double digits sequentially and ZEJULA steadied. Operating expenses are expected to stay broadly flat through year-end, the practical definition of operating leverage waiting on the top line. Notably, Zai Lab's call is one of the few this earnings season that never mentions tariff refunds — a hot theme across dozens of reporters in the last five days — a reminder of how insulated the China-licensing model is from the U.S. trade cycle. **ZL-1503: the second global bet** The pipeline beyond Zoci is where the long-term upside sits. ZL-1503, the IL-13/IL-31 bispecific with YTE half-life extension, is early but positions Zai in the hot atopic dermatitis race — a theme the market tape is already cheering, with severe atopic dermatitis names among the 360-day advancers. An analyst pressed on the increasingly crowded space, noting a fresh IPO in the same IL-13/IL-31 area. Rafael's answer leaned on the molecule's triple claim — “designed to break the itch scratch inflammation cycle with rapid durable efficacy and less frequent dosing” — Rafael Amado, President and Head of Global Research and Development · 2026-08-06 — while admitting doses are still being worked out. The healthy volunteers SAD data, due in 2H 2026, and MAD data in AD patients next year are the near-term derisking catalysts, with the assay already tracking PD biomarkers like pSTAT6, TARC and CCL26. Zai's genuinely differentiated claim — targeting IL-13 plus the IL-31 receptor with a long half-life — is a strong ad versus a growing field, and it explains why the company is in no hurry to marry the ZL-1503 profile to a concessionary profit timeline. This is a company in transition, and the market is rewarding the transition even as management intentionally defers the profit milestone that was once a headline commitment. The question investors will keep asking is whether Zoci's 2028 U.S. launch — and the IL-13/IL-31 data derisking ZL-1503 along the way — arrive fast enough to justify the patience.so right now, our responsibility is to invest where the returns justify it... we are kind of growing revenue with our potential global approval in 2028, which will improve margin and drive operating efficiencies across the organization at the same time. So we believe those factors adding together will naturally lead to the profitability over time.